Research into the detection of cancer using advanced technologies has become a global endeavor. Earlier this year, Intel and the UK's National Health Service revealed they are working towards creating a digital repository of cancer information that will be used by algorithms to recognize these cells automatically. Australia's Commonwealth Scientific and Industrial Research Organization (CSIRO) Data61 division has been working on the development of software that enables the detection of new blood vessels that precede the growth of cancers. Guardant Health, Freenome, and Grail are United States based start ups that target early cancer detection through the use of technology and have all recently raised multi-million dollar investments.
Japan has presented results that show their artificial intelligence-powered system analyzed more than 300 colorectal adenomas in 250 patients and was able to determine with 94 percent accuracy the malignancy of the tumors. Researchers claim the software is able to detect benign tumors that can evolve into cancer in less than 1 second. The remarkable breakthrough described by the study leader Dr Yuichi Mori is that the software allows for real-time biopsy regardless of the endoscopists' expertise. The high level of accuracy gives the researches hope that clinical application and regulatory approval will soon follow.
Click here to read the full article.
Japan has presented results that show their artificial intelligence-powered system analyzed more than 300 colorectal adenomas in 250 patients and was able to determine with 94 percent accuracy the malignancy of the tumors. Researchers claim the software is able to detect benign tumors that can evolve into cancer in less than 1 second. The remarkable breakthrough described by the study leader Dr Yuichi Mori is that the software allows for real-time biopsy regardless of the endoscopists' expertise. The high level of accuracy gives the researches hope that clinical application and regulatory approval will soon follow.
Click here to read the full article.
